Nov 04, 2021 / 08:00AM GMT
Naoki Muto - Terumo Corporation - Chief Accounting & Financial Officer and Executive Officer
I am the CAFO, Muto. I will now explain the second quarter results for the fiscal year ending March 2022. First, the highlights from the quarter. Sales and profit were both our highest ever. In sales revenue, demand for Cardiac and Vascular Company products made a significant recovery from COVID-19 impact. Although that company was somewhat affected by a repeated wave of COVID due to the Delta variant, the other 2 companies covered that impact.
In adjusted operating profit, a recovery in sales and product mix improvement both contributed. Expenses including SG&A, which rose slowly in the first quarter, progressed as planned in the second quarter. There is no change in the guidance for the full fiscal year, but we will raise the dividend to JPY 32 from the previous JPY 30. We anticipate a continued recovery of demand for procedures in the second half, which will bring our results into a growth pattern. However, amid what is expected to become a more concerning situation of higher freight costs due
Q2 2022 Terumo Corp Earnings Call Transcript
Feb 15, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers